Ekso Bionics market cap is $43.8 m, and annual revenue was $11.33 m in FY 2018

Ekso Bionics Gross profit (Q3, 2019)1.8 M

Ekso Bionics Gross profit margin (Q3, 2019), %52.7%

Ekso Bionics Net income (Q3, 2019)206 K

Ekso Bionics EBIT (Q3, 2019)-3.8 M

Ekso Bionics Cash, 30-Sept-20198.1 M

Ekso Bionics EV36.7 M

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Revenue | 5.3m | 8.7m | 14.2m | 7.4m | 11.3m | |

## Cost of goods sold | 3.8m | 7.5m | 11.3m | 5.3m | 7.0m | |

## Gross profit | 1.6m | 1.2m | 2.9m | 2.1m | 4.3m | |

| 29% | 14% | 21% | 28% | 38% | |

## Sales and marketing expense | 7.1m | 9.3m | 11.0m | 13.2m | 13.8m | |

## R&D expense | 3.9m | 6.5m | 8.9m | 9.5m | 5.8m | |

## General and administrative expense | 1.4k | 7.4m | 7.0m | 10.9m | 10.7m | 11.7m |

## Operating expense total | 1.4k | 18.4m | 22.7m | 30.5m | 33.7m | 31.3m |

## EBIT | (12.3k) | (16.8m) | (21.6m) | (27.6m) | (31.6m) | (27.0m) |

| (315%) | (249%) | (194%) | (430%) | (239%) | |

## Interest expense | 61.0k | 5.0k | 166.0k | 2.5m | 38.0k | |

## Interest income | 6.0k | 11.0k | 12.0k | |||

## Pre tax profit | (33.6m) | (19.6m) | (23.5m) | (29.1m) | (27.0m) | |

## Income tax expense | ||||||

## Net Income | (12.3k) | (33.8m) | (19.6m) | (23.5m) | (29.1m) | (27.0m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 29.2k | 25.2m | 19.6m | 16.8m | 27.8m | 7.7m |

## Accounts Receivable | 1.5m | 2.1m | 2.8m | 3.7m | ||

## Prepaid Expenses | 388.0k | 436.0k | 1.3m | 281.0k | ||

## Inventories | 622.0k | 1.1m | 1.6m | 3.0m | 3.4m | |

## Current Assets | 29.3m | 25.2m | 20.7m | 34.9m | 15.0m | |

## PP&E | 2.1m | 2.6m | 2.4m | 2.2m | 2.4m | |

## Goodwill | 189.0k | 189.0k | 189.0k | 189.0k | ||

## Total Assets | 29.2k | 33.5m | 32.2m | 24.4m | 38.0m | 17.7m |

## Accounts Payable | 783.0k | 2.7m | 1.9m | 2.4m | 3.2m | |

## Short-term debt | 41.0k | 80.0k | 2.1m | 2.3m | ||

## Current Liabilities | 6.6m | 8.6m | 6.3m | 9.2m | 10.1m | |

## Long-term debt | 77.0k | 4.8m | 2.6m | |||

## Total Debt | 118.0k | 7.0m | 5.0m | |||

## Total Liabilities | 14.1k | 10.7m | 23.4m | 17.9m | 16.6m | 14.9m |

## Common Stock | 6.4k | 102.0k | 105.0k | 60.0k | 63.0k | |

## Preferred Stock | ||||||

## Additional Paid-in Capital | 94.5m | 100.1m | 121.3m | 165.8m | 173.9m | |

## Retained Earnings | (16.9k) | (71.8m) | (91.4m) | (114.9m) | (144.2m) | (171.1m) |

## Total Equity | 15.1k | 22.8m | 8.8m | 6.5m | 21.4m | 2.7m |

## Financial Leverage | 1.9 x | 1.5 x | 3.7 x | 3.7 x | 1.8 x | 6.5 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | (12.3k) | (33.8m) | (19.6m) | (23.5m) | (29.1m) | (27.0m) |

## Depreciation and Amortization | 745.0k | 933.0k | 1.9m | 1.7m | 1.5m | |

## Accounts Receivable | (1.0m) | (520.0k) | 154.0k | (1.1m) | (850.0k) | |

## Inventories | 354.0k | (200.0k) | (541.0k) | (2.1m) | (1.7m) | |

## Accounts Payable | 300.0 | (716.0k) | 1.7m | (818.0k) | 77.0k | 752.0k |

## Cash From Operating Activities | (12.0k) | (15.0m) | (18.3m) | (25.0m) | (31.2m) | (22.2m) |

## Purchases of PP&E | (1.5m) | (1.5m) | (1.1m) | (456.0k) | (131.0k) | |

## Cash From Investing Activities | (1.5m) | (1.5m) | (1.1m) | (456.0k) | (131.0k) | |

## Short-term Borrowings | (2.6m) | (60.0k) | (79.0k) | (54.0k) | (2.2m) | |

## Cash From Financing Activities | 32.7k | 40.9m | 14.1m | 23.3m | 42.6m | 2.3m |

## Net Change in Cash | 20.7k | 24.4m | (5.6m) | (2.7m) | 11.0m | (20.2m) |

## Interest Paid | 138.0k | 5.0k | 33.0k | 20.0k | 18.0k | |

## Income Taxes Paid | 38.0k | 12.0k | 16.0k | 429.0k | 457.0k |

USD | Y, 2019 |
---|---|

## EV/EBIT | -9.7 x |

## EV/CFO | -2.6 x |

## Debt/Equity | 0.2 x |

## Financial Leverage | 3.2 x |